Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Gilead Sciences Inc.’s stock climbed 3% early Thursday after the company said its twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, building the case for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences rose 2% in early trading, after the biotech reported positive data for a long-acting HIV prevention drug that promises to be a big seller. The drug, called lenacapavir, was 96% ...

Gilead Sciences Inc. closed $3.98 short of its 52-week high ($87.87), which the company achieved on January 19th.

Gilead Sciences reported good quarterly results and in the last few weeks, the stock rallied higher. Oncology will especially contribute to growth in the years to come, and maybe Gilead Sciences ...

About Gilead Sciences: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.

Originally published by Gilead Sciences View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Together, we drive innovation and further our mission to create a healthier world for all people. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and ...